🚀Curing uncured diseases 🧪Bio+AI geek: https://xitter.cf/t.co/j91L2vgEgK 🤖Open-source JAX ecosystem: https://xitter.cf/t.co/0mZ8rIcYsu 🤿Scuba, sailing
Mostly Zürich. I travel a lot.
Joined July 2020
- Tweets1.3K
- Following252
- Followers11.9K
- Likes1.1K
Pinned Tweet
⚡️ My PhD thesis is on arXiv! ⚡️
To quote my examiners it is "the textbook of neural differential equations" - across ordinary/controlled/stochastic diffeqs.
w/ unpublished material:
- generalised adjoint methods
- symbolic regression
- + more!
arxiv.org/abs/2202.02435
v🧵 1/n
Update: I've now *also* had multiple JAX-for-{fusion,molecular dynamics,...} companies ask me for referrals in the exact same way.
I need to start hosting a job board haha
What the 'neopharma' discussion misses is that this is a class of companies, as "software" is a class. The VC pitch is the layer of detail below. Modality/in vivo data/etc.
If you want to distinguish the serious/unserious, ask them what their GLP-tox strategy is.
A lot of this is just Stanford/ Valley money
Like it's a bit inconsequential that these companies are AI x Bio. It's more of the fact that they are valley ppl. AI x Bio outside the valley or without deep Boston ties have no shot at raising this kind of money even if they're doing the same thing verbatim
Patrick Kidger retweeted
The degree of target clustering in pharma right now is absolute madness. How is this not objectively idiotic?
The pendulum will swing back to unique/novel MoAs eventually…it just has to.
Right now you can get VALIDATED novel/unique MoAs for less than some of these me-80 drugs in some cases. The system seems broken.
As usual, doing my bit to talk about bio topics in front of my AI audience: COINS (home.treasury.gov/news/press…) a possible rule to restrict US investments/JVs with Chinese biotech, released yesterday.
My guess is that this will backfire the same way that the GPU blockade did: it will just result in a stronger competitor.
And China's homegrown industry is already arguably the strongest (?) in the world. I don't have a stat for that, but it's noticeable from the ground: e.g. Chinese CROs actually respond to their emails same-day instead of next-week; WuXi clearly the market-leading biologics CDMO; etc.
AI+bio: the Escalante folks released a blog post yesterday, and as usual it's a banger, talking more about their multiplexed protein binding assay:
blog.escalante.bio/endless-p…
(I imagine this got lost amidst the securitypocalypse that landed yesterday.)
Great to see more API-for-biology companies out there (alongside Adaptyv, Biointron, Ginkgo, etc.) Warp looks chemistry-inflected (unlike a lot of the protein-focused ones we see).
We still need more of this for the 'harder' properties: immunogenicity/T-cell activation, etc.
💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster.
We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America.
I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.
Patrick Kidger retweeted
Excited to announce the follow-up to our NeurIPS 2026 Oral: Improved Training of Strong Stochastic Flow Maps!
We improve the training of SSFMs by unlocking derivative-based losses!
Joint work with @antoniofrancaib @rmincam @ChristianKoke @Niklas_TR and @AlexanderTong7
Patrick Kidger retweeted
Lots of VCs kindof sound like this: "Your basketball team doesn't have a moat, any healthy human can throw the ball into the basket thingy. "
People who have not run companies before don't understand how much the team matters more than some imagined structural moat.
The Radical Numerics team knocking it out the park as always! 🚀
As for all the debate around whether AI therapeutics are reaching patients. Here they're canonically claiming exactly that, no matter how you slice it.
I'm pretty excited. Let's examine some highlights:
1/
(from the grapevine) burned a lot of folks in big pharma. So hmmmm RN I would love to hear more about what you're up to. :D
Second, the use of large genomic data. This is kind of old hat in genomics now (a lot from the past public work done by the RN founders
6/